Table of Contents
What changed
Revenue rose 8.1% to $211.9m on 11% volume growth, with the galvanizing acquisition cited as the primary driver. Reported EBITDA doubled from $0.6m to $1.2m (normalised $2.8m), but the loss before tax widened 19.7% to -$17.1m and NPAT widened 19.3% to -$12.4m. The standout movement is on the balance sheet and cash: operating cash flow collapsed 75.9% to $5.6m from $23.1m, cash fell to $7.0m from $17.5m, and the group recorded $50.0m of gross borrowings versus nil a year ago. Net cash of $17.5m in HY25 has become approximately $43.0m of net debt. No dividend was declared.
What matters
- Balance sheet reversal. The swing from net cash to ~$43.0m net debt, combined with an 8.0% decline in total equity to $170.4m and a 49.4% jump in total liabilities to $222.8m, is the dominant read. On reported EBITDA of $1.2m, net debt/EBITDA is not a meaningful ratio — it simply reflects that earnings are not yet covering even modest leverage.
- Earnings quality despite headline EBITDA doubling. Reported EBITDA moved from $0.6m to $1.2m, but PBT deteriorated by $2.8m and the PBT-NPAT growth gap is only 0.4pp, so tax distortion is not the issue. The cleaner read is that the acquisition added earnings while the base business margin squeeze offset the benefit, leaving the operating loss wider.
- Working capital absorption. Trade debtors jumped 28.9% to $54.2m (receivable days 46.6 vs 39.0) while inventories rose 5.8% to $115.9m. Proxy operating working capital rose ~$18.5m, which is broadly the shape of the OCF shortfall.
Expectations
No FY26 quantitative guidance, forward work or backlog is disclosed in the provided material, and the company has not stated a target. Annualising HY26 revenue gives ~$423.8m, above FY25's $385.4m, consistent with acquisition contribution. However, in the prior year the second half was weaker than the first on EBITDA (implied -$3.1m vs +$0.6m) and NPAT (-$14.0m vs -$10.4m), so there is no historical seasonal tailwind to lean on. The release supports a view that volumes and revenue can grow, but it does not support a view that reported profitability will turn positive without further margin recovery or cost-out.
Quality of result
Low. The revenue growth is real but the 2x EBITDA headline is against a very low base of $0.6m and is non-cash in effect: pre-lease free cash flow fell to $1.8m from $19.3m. The OCF deterioration is driven by working capital rather than a one-off timing item disclosed in the filing, and the $1.6m gap between normalised ($2.8m) and reported ($1.2m) EBITDA is not itemised in the supplied material. Cash conversion deteriorated materially and should be flagged as such. Capex at $3.8m (1.8% of revenue) is steady and not the issue.
Unresolved
- What is the bridge between reported $1.2m and normalised $2.8m EBITDA, and are those adjustments genuinely non-recurring?
- What are the terms, covenants and headroom on the $50.0m drawn borrowings, and what facility size sits behind it versus the $100m facility referenced a year ago?
- How much of the 8.1% revenue growth and the volume lift is organic versus galvanizing acquisition contribution, and what is the base-business margin trajectory?
- What is driving receivable days extending by 7.5 days — is it mix shift to acquisition customers, weaker collections, or channel change?
- Is management targeting a return to positive reported EBITDA and net cash in FY26, and on what volume/margin assumptions?
This briefing cannot assess segment-level profitability, share-price valuation, or covenant risk, because none of those items are disclosed in the supplied data.
Key metrics
| Metric | HY26 | HY25 | Change |
|---|---|---|---|
| Revenue | $211.9m | $196.0m | +8.1% ↑ |
| EBITDA | $1.2m | $0.6m | +100.0% ↑ |
| Net profit after tax | −$12.4m | −$10.4m | -19.3% ↓ |
| Net cash inflow from operating activities | $5.6m | $23.1m | -75.9% ↓ |
| Profit before tax | −$17.1m | −$14.3m | -19.7% ↓ |
| Cash and cash equivalents | $7.0m | $17.5m | -60.2% ↓ |
| Total assets | $393.2m | $334.3m | +17.6% ↑ |
Analytical metrics
| Metric | HY26 | HY25 | Context |
|---|---|---|---|
| OCF / EBITDA (cash conversion) | 464.8% | n/m | deteriorated |
| FCF pre-lease | $1.8m | $19.3m | −$17.4m |
| FCF post-lease | $1.8m | $19.3m | −$17.4m |
| FCF / NPAT | -14.7% | -185.3% | complementary conversion metric |
| Capex % revenue | 1.8% | 2.0% | — |
| Capex | −$3.8m | −$3.9m | +$0.1m |
| Debtor days | 46.5 | 39.0 | +7.5 days |
| Inventory days | 99.6 | 101.8 | -2.2 days |
| Operating working capital | $170.1m | $151.6m | +$18.5m absorbed |
| Trade debtors | $54.2m | $42.0m | +$12.1m |
| Net debt | $43.0m | −$17.5m | +$60.5m |
| Net debt / EBITDA | 35.86x | -29.19x | Weakening |
| Gross borrowings | $50.0m | — | — |
| ROE (annualised) | -14.6% | -11.2% | Weakening |
| HY25 share of FY25 revenue | 50.9% | — | Other half was 49.1% |
| HY25 share of FY25 EBITDA | -24.0% | — | Other half was 124.0% |
| HY25 share of FY25 NPAT | 42.7% | — | Other half was 57.3% |
| Profit from continuing operations | −$12.4m | −$10.4m | −$2.0m |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.